psilocybin (COMP360) / Compass Pathways 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...234567891011121314»
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Evaluation of psilocybin production under home brewing conditions (Exhibit Hall D, Pennsylvania Convention Center) -  Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_13480;    
    We will use High Performance Liquid Chromatography (HPLC) to analyze the psilocybin titer and to compare home-brewing and bioreactor production conditions. All work with scheduled drug compounds is performed in an approved laboratory and all required safety and waste disposal regulations were followed.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Gram-scale production of psilocybin in E. coli (Exhibit Hall D, Pennsylvania Convention Center) -  Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_13459;    
    The process to achieve these titers includes screening of multiple defined and random transcriptionally-varied libraries as well as a combinatorial analysis on the effects of varying induction conditions, temperature, and media supplements on overall product titer. Our continuing work towards developing a better understanding of the production landscape of this strain as well as the development of a more efficient and stable strain to further enhance psilocybin production in E. coli will also be discussed.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Evaluation of psilocybin production under home brewing conditions (Exhibit Hall A, Pennsylvania Convention Center) -  Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_8164;    
    We will use High Performance Liquid Chromatography (HPLC) to analyze the psilocybin titer and to compare home-brewing and bioreactor production conditions. All work with scheduled drug compounds is performed in an approved laboratory and all required safety and waste disposal regulations were followed.
  • ||||||||||  ketamine / Generic mfg., lithium / Generic mfg., psilocybin / Compass Pathways
    Review, Journal:  Management of Treatment-Resistant Depression: Challenges and Strategies. (Pubmed Central) -  Feb 6, 2020   
    Somatic therapies, including several modalities of brain stimulation (electroconvulsive therapy, repetitive transcranial magnetic stimulation, magnetic seizure therapy and deep brain stimulation) are detailed, psychotherapeutic strategies and subsequently novel therapeutics including ketamine, psilocybin, anti-inflammatories and new directions are reviewed in this manuscript. Our review of the evidence suggests that further large-scale work is necessary to understand the appropriate treatment pathways for TRD and to prescribe effective therapeutic options for patients suffering from TRD.
  • ||||||||||  psilocybin / Compass Pathways
    Journal:  Replication and extension of a model predicting response to psilocybin. (Pubmed Central) -  Jan 29, 2020   
    Mental states of surrender or preoccupation at the time of ingestion explain variance in mystical or adverse psilocybin experiences, and mystical experiences relate to long-term positive change. The capacity to recognize this optimal preparatory mental state may benefit therapeutic use of psilocybin in clinical settings.
  • ||||||||||  psilocybin / Compass Pathways
    Review, Journal:  Addictions (Pubmed Central) -  Jan 28, 2020   
    A brief literature review about vaping confirms its interest in quitting cigarette, with a cost of addiction to vaping and recent worrisome reports of chemical pneumonia. Finally, the withdrawal of WHO guidelines on opiates use in pain management, in the context of a suspicion of conflict of interest, underlines the sensible balance between over- and under- prescription of opiates in analgesic treatment.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Trial completion date, Trial primary completion date:  The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (clinicaltrials.gov) -  Jan 27, 2020   
    P2,  N=216, Recruiting, 
    Finally, the withdrawal of WHO guidelines on opiates use in pain management, in the context of a suspicion of conflict of interest, underlines the sensible balance between over- and under- prescription of opiates in analgesic treatment. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Aug 2020
  • ||||||||||  ketamine / Generic mfg., psilocybin / Compass Pathways
    Social Psychopharmacology: A New Era of Psychedelic-Assisted Group Therapy and Support () -  Jan 21, 2020 - Abstract #APA2020APA_319;    
    Mixed-method data utilizing qualitative and quantiative speech analyses, behavioral outcomes, and patient/group vignettes and de-identified transcripts will be presented for use in small group roleplaying. Attendees will be given an opportunity to ask the presenters about the relevant history, current state and future pathways of this new era of social psychopharmacology, in which the famous adage of "drug, set, and setting" (Zinberg 1984) is being explored, expanded and continually iterated to boost group therapy and optimize the risk-benefit ratio of consciousness-altering medications by leveraging therapeutic holding and containment in group process and collective settings.
  • ||||||||||  ketamine / Generic mfg., psilocybin / Compass Pathways
    The Psychedelic Renaissance and Its Forensic Implications: Violence Risk Assessment and Evaluation Considerations () -  Jan 21, 2020 - Abstract #APA2020APA_164;    
    Like cannabinoids, MDMA, ketamine, and other psychoactive substances, however, psychedelics are once again seeing their day in clinical research trials for conditions including addiction and terminal illness-related anxiety...In addition, in May of 2019 Denver become the first jurisdiction of the United States to decriminalize psilocybin-containing mushrooms...In addition, they will describe and assess the available literature regarding psychedelic use and the associated risk for violence, including initial case reports and more recent large-scale epidemiologic studies. Attendees will learn about practical considerations in the assessment of psychedelic use, such as the impact of “set” and “setting” on psychedelic experiences, and how to identify characteristics of use that are more likely to result in violence or other negative outcomes.
  • ||||||||||  psilocybin / Compass Pathways
    Treating Substance Use Disorders With Classic Psychedelics () -  Jan 21, 2020 - Abstract #APA2020APA_93;    
    Michael Bogenschutz will review data from a previous pilot study of psilocybin treatment of alcohol use disorder and an ongoing double-blind study comparing psilocybin with diphenhydramine treatment. Bryon Adinoff will discuss the promising results of these trials, possible neurobiological mechanisms, and the implications for future research with psilocybin and other psychedelics for the treatment of substance use disorders.
  • ||||||||||  psilocybin / Compass Pathways
    Preclinical, Journal:  Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. (Pubmed Central) -  Jan 11, 2020   
    Psilocin and psilocybin showed no antidepressant-like effect in the FSL rats, despite a positive effect in humans. This suggests that other animal models of depression and other behavioural tests may be more appropriate for translational studies in the effects of psilocybin.
  • ||||||||||  psilocybin / Compass Pathways
    Journal:  Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. (Pubmed Central) -  Dec 21, 2019   
    We report for the first time that intake of psilocybin leads to significant 5-HT2AR occupancy in the human brain, and that both psilocin plasma levels and 5-HT2AR occupancy are closely associated with subjective intensity ratings, strongly supporting that stimulation of 5-HT2AR is a key determinant for the psychedelic experience. Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.